Suntinorexton

Last updated

Suntinorexton
Suntinorexton.svg
Clinical data
Drug class Orexin OX2 receptor agonist
Identifiers
  • N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
CAS Number
PubChem CID
UNII
Chemical and physical data
Formula C23H28F2N2O4S
Molar mass 466.54 g·mol−1
3D model (JSmol)
  • CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O
  • InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1
  • Key:MQDUVMBBJZLFHF-PMACEKPBSA-N

Suntinorexton (INN Tooltip International Nonproprietary Name) is an experimental orexin receptor agonist. [1] It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company. [2] It is being evaluated for the treatment of narcolepsy. [3]

See also

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020. Proposed INN: List 123
  2. ↑ WOapplication 2019027058,Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K,"Heterocyclic compound and use therof",published 2019-02-07, assigned to Takeda Pharmaceutical Company.
  3. ↑ Konofal E (August 2024). "From past to future: 50 years of pharmacological interventions to treat narcolepsy". Pharmacology, Biochemistry, and Behavior. 241 173804. doi: 10.1016/j.pbb.2024.173804 . PMID   38852786.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.